Which hedge funds own INBX? INHIBRX BIOSCIENCES INC, Q2 2026 13F holders
36 tracked hedge funds disclosed a position in INBX (INHIBRX BIOSCIENCES INC) in their Q2 2026 13F filings, worth $477.2m in total. The largest holder by portfolio weight is PFM Health Sciences, LP at 2.5% of its book. 17 opened a new position this quarter: Parkman Healthcare Partners LLC, Cannon Global Investment Management, LLC, Western Standard LLC, Ratan Capital Management LP. 9 exited: Soleus Capital Management, L.P., Centiva Capital, LP, Seven Fleet Capital Management LP.
- 36
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 17
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 9
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $42.9m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $14.2m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $477m
- Combined value Sum of the holders' reported positions in the security.
- 2.9%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Soleus Capital Management, L.P. | 0.4% | $8.8m |
| Centiva Capital, LP | 0.06% | $1.2m |
| Seven Fleet Capital Management LP | 0.05% | $167k |
| Mangrove Partners IM, LLC | 0.03% | $372k |
| Aquatic Capital Management LLC | 0.01% | $489k |
| Graham Capital Management, L.P. | 0.01% | $352k |
| Caption Management, LLC | 0.0% | $67.2k |
| Tudor Investment Corp ET AL | 0.0% | $496k |
| Citadel Advisors LLC | 0.0% | $2.2m |
Ownership over time
Who discovered INBX first? Beta
| Perceptive Advisors LLC | Q3 2025 | +2.9 pts |
| Sofinnova Investments, Inc. | Q3 2025 | +2.5 pts |
| PFM Health Sciences, LP | Q4 2025 | +1.9 pts |
| Caligan Partners LP | Q4 2025 | +1.5 pts |
| Slotnik Capital, LLC | Q2 2024 | +1.5 pts |
| Ikarian Capital, LLC | Q2 2024 | +0.1 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.